Avalyn Pharmaceuticals
MA - CambridgePharmaceutical
Focus: Avalyn Pharmaceuticals is a public-stage biotech company focused on therapies for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, operating as a lean 1-50 person organization from Cambridge, MA.
Profile data last refreshed 16h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
1-50
Total Funding
$150M
Open Jobs
8
Should You Work at Avalyn Pharmaceuticals?
AI assessmentBest suited for early-stage operators and mission-driven scientists willing to accept structural risk for meaningful IPF/PF research impact in a lean, capital-efficient setting.
Why Work Here
- Focused pipeline in high-unmet-need respiratory space with 2 Phase 2 programs advancing (nintedanib for IPF, AP01 for progressive pulmonary fibrosis).
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 2
Clinical Trials (2)
NCT06329401A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Phase 2Help build intelligence for Avalyn Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.